subscribeSubscribe
Reata culls bardoxolone, ending decade of R&D on troubled kidney disease drug

Reata culls bardoxolone, ending decade of R&D on troubled kidney disease drug
Kyle LaHucik ENDPTS
11 May 2023
Share Share
Reata, Kyowa Kirin ax bardoxolone, ending 13-year saga

Reata, Kyowa Kirin ax bardoxolone, ending 13-year saga
Max Bayer FIERCE BIOTECH
10 May 2023
Share Share
Reata Pharma to Report 2nd Quarter 2022 Financial Results

Reata Pharma to Report 2nd Quarter 2022 Financial Results
BUSINESSWIRE
01 Aug 2022
Share Share
Reata slips as FDA rejects kidney disease therapy

Reata slips as FDA rejects kidney disease therapy
D. Lokuwithana SEEKING ALPHA
26 Feb 2022
Share Share
FDA slams Reata`s kidney drug as ineffective ahead of adcomm meeting

FDA slams Reata`s kidney drug as ineffective ahead of adcomm meeting
Zachary Brennan ENDPTS
06 Dec 2021
Share Share
Reata , Inc. Submits NDA for Company’s Lead Program: Bardoxolone

Reata , Inc. Submits NDA for Company’s Lead Program: Bardoxolone
GLOBENEWSWIRE
01 Mar 2021
Share Share
Reata Announces +VE Results From 2y of the Pivotal Ph3 Study of Bardoxolone

Reata Announces +VE Results From 2y of the Pivotal Ph3 Study of Bardoxolone
PRESSRELEASE
09 Nov 2020
Share Share
Reata Announces Initiation Investigator-Sponsored Study Evaluating Bardoxolone

Reata Announces Initiation Investigator-Sponsored Study Evaluating Bardoxolone
GLOBENEWSWIRE
27 Jul 2020
Share Share
Two preclinical biotechs riding the IPO wave this week look to raise $466M-plus

Two preclinical biotechs riding the IPO wave this week look to raise $466M-plus
John Carroll ENDPTS
11 Jun 2020
Share Share
Reata`s bardoxolone offers promise in patients with rare kidney disorder

Reata`s bardoxolone offers promise in patients with rare kidney disorder
Natalie Grover ENDPTS
12 Nov 2019
Share Share